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CAPSTONE EXPERIENCE
Abstract
Objectives: To evaluate the role of preexisting Angiotensin II receptor type I
antibodies (AT1RAb) and anti-HLA antibodies in predicting mortality and cardiac
allograft vasculopathy (CAV) among heart transplant patients.
Methods: In this retrospective cohort study, we included 114 adults who received
heart transplant from January 1st, 2007 to December 31, 2014 and were followed up
at Nebraska Medicine. 48 hours pre-transplant sera sample were used to detect
antibodies. A cutoff of 10UL/ml was used for AT1RAb positive and mean
fluorescence intensity of 3,000 and 1,500 were used for anti HLA class I and class
II, respectively. Patients were positive for composite antibodies if they were positive
for anti-HLA, or AT1R antibodies. Survival analysis was conducted to compare the
risk for mortality or CAV between antibody positive and negative groups.
Result: Participants who had positive composite antibodies had higher probability
of having CAV (p=0.05). Participants who were negative for AT1RAb trended toward
a lower risk of mortality or developing CAV compared to AT1RAb positive
counterparts.
Conclusion: Positive status for any of anti-HLA or AT1RAb increased the risk of
CAV. AT1RAb positivity is possibly linked with higher risk of death or developing
CAV. Future study can focus on verifying these trends and the potential interaction
effect between anti-HLA and AT1R antibodies.
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INTRODUCTION
Heart transplantation is the treatment of choice for end-stage heart disease.
Since the first human heart transplant in 1967, the number of heart transplantation
has increased rapidly worldwide. According to the 2014 International Society for
Heart and Lung Transplantation (ISHLT) official report, there were 104,027 heart
transplants through June 30th, 2013 globally (Lund et al., 2014). In the United
States, there were about 2,500 cases conducted in the year 2012 (The International
Society of Heart and Lung Transplantation, 2014). Mortality rates in heart
transplantation have been reducing for every ten years, with the mortality rate in
the first year after transplantation is about 15% in the cohort of patients
transplanted in 2006 to 2012 (Lund et al., 2014). There are several factors that are
associated with a higher risk of death up to 1 year after transplant. These factors
include recipients’ pre-transplant severity of illness (measured by pre-operation
hospitalization, mechanical ventilation, and temporary mechanical circulatory
support), history of dialysis or blood transfusion, renal failure, and older age (Lund
et al., 2014).
However, heart transplantation is not considered a curative therapy for heart
disease because of the long-term complications or comorbidities. These
complications include blood marrow suppression, opportunistic viral infection,
malignancy, graft loss, graft dysfunction and even mortality (Griffin, Callahan, &
Menon, 2012). Comorbidities, which contribute to graft failure and graft loss, are
also common in heart transplant patients. The prevalence of chronic disease in heart
transplant patients higher than that in general population, and increase with posttransplantation course. Specifically, prevalence of hypertension, hyperlipidemia,
2

cardiac allograft vasculopathy, and diabetes at 10 year post-transplantation are 97%,
93%, 59% and 39% respectively (The International Society of Heart and Lung
Transplantation, 2014). Nonetheless, estimation of comorbidities at certain
predetermined time point, such as ten year, does not account for dead patients and
therefore underestimate the real prevalence.

Recipient selection
In general, patients are considered for heart transplantation when they have
severe heart failure that does not response with medical or mechanical treatment.
Peak exercise maximum oxygen consumption and percentage to predict maximum
oxygen consumption are usually used to objective evaluate heart function. Common
indications for heart transplantation are listed in Table 1 (Pham, Berry, & Hunt,
2011):
Table 1: Commonly Accepted Indications for Cardiac Transplantation
• Systolic heart failure with severe functional limitations or refractory
symptoms despite maximal medical and device therapy
• LVEF usually <35%, but a low LVEF is not an adequate indication for
transplantation
• NYHA functional class III-IV
• Maximal oxygen uptake (VO2max) of ≤12-14 cc/kg/min exercise testing
• Cardiogenic shock not expected to recover
• Acute myocardial infarction
• Acute myocarditis
• Ischemic heart disease with intractable angina not amenable to surgical or
percutaneous revascularization and refractory to maximal medical therapy
• Intractable ventricular arrhythmias, uncontrolled with standard
antiarrhythmic therapy, device therapy, or ablative therapy
• Severe symptomatic hypertrophic or restrictive cardiomyopathy
• Congenital heart disease in which severe, fixed pulmonary hypertension is
not a complication
• Cardiac tumors with a low likelihood of metastasis
LVEF: Left ventricular ejection fraction. NYHA: New York Heart Association
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Before being selected for transplantation, heart failure patients need to
undergo a series of tests and examination to ensure that they will be an appropriate
recipient. These measurements include clinical examination, family, social and
medical history, standard serum and a 12-h urine collection laboratory tests.
Table 2: Contraindications for cardiac transplantation (Liao &
Shumway, 2014)
Relative contraindication:
• Advanced age (>70)
• Active myocarditis
• Graft failure due to acute rejection
Temporary contraindications for cardiac transplantation
• Active infection
• Active peptic ulcer disease
• Diverticulitis
• Recent pulmonary/cerebral emboli
• Symptomatic cholelithiasis
Absolute contraindications for cardiac transplantation
• Positive prospective cross-match
• Irreversible pulmonary hypertension (pulmonary vascular resistance ≥ 5
Wood units)
• Malignancy
• Severe peripheral or cerebral vascular disease
• Irreversible renal dysfunction (Glomerular Filtration Rate ≤40 ml/min)
• Irreversible hepatic dysfunction
• Severe obstructive or restrictive lung disease
• Coexisting systemic disease
• Diabetes mellitus with end-organs disease
• Morbid obesity (≥30% or predicted ideal weight) or BMI ≥ 35
• Severe cachexia
• Ongoing tobacco use or drug addiction
• Ongoing alcohol abuse
• Noncompliance with medications
• Inability to fully understand the procedure and participate in follow-up care
Potential receivers are also ruled out of cancer with negative results from
stool guaiac, mammography, prostate-specific antigen screening, Pap-smear. Tests
of occult infections including hepatitis B and C, HIV, HTLV1, and HTLV2,
4

cytomegalovirus, Toxoplasma, Epstein–Barr virus, syphilis, and tuberculosis are
also carried out before selection for transplantation is made. Pre-transplant data
also include blood type, HLA–DR typing, and panel reactive antibody (PRA)
screening (Liao & Shumway, 2014). Certain conditions that limit patients from
being a recipient are listed in Table 2.

Donor selection
The donors are usually younger than 50 year old and do not have history of
chest trauma or heart disease. Donor exclusion criteria include: malignancy with
potential of metastasis to the heart, systemic sepsis or endocarditis, significant
coronary artery disease, anatomical heart disease or poor ventricular function.
While waiting for transplantation, the donor heart need to avoid prolong
hypotension or hypoxemia. However, inotrope should be used as least as possible to
reduce the oxygen demand of the donor heart.
There are several technique to preserve the donor heart, including
hypothermia, cardioplegia, and preservation solutions. Cardioplegia is used to
arrest the heart while preservation solution is used to keep the heart at 4 to 8 Celsius
degree to reduce metabolism. However, all measures together, the donor heart is
usually only kept for to 4-6 hour of cold ischemic time. Due to the shortage of donors
and the increasing demand, the selection of donor heart is widening beyond some
classic contraindications. These expended criteria include longer ischemic time,
mild valvular abnormalities, mild coronary artery abnormalities or mild left
ventricular dysfunction (Pham et al., 2011).
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Matching recipients and donors
In order to anatomically matched heart size, the donors’ and recipients’
weight should also stay in the range from 80% to 120% of each other. However, body
weight is not a sensitive tool to estimate the heart size. Chan et al. reported no
correlation between body weights and heart size in adults who weigh from 40 to 99
kg (Chan et al., 1991). With the expansion of donor pool, older donors are becoming
more common. In such cases, an older recipient with similar life expectancy is
usually chosen for transplant (Esmore, 2005). Donor and recipient should have the
same ABO blood group, or compatible blood group. Recipients are also tested for
panel reactive antibody (PRA). Potential recipients in the transplant waiting list who
have PRA positive more than 20% should be checked for their antibody status every
two months. A PRA test positive more than 20% just before transplant requires
actually donor-specific T cell cross-matches to see if donor specific antibodies are
present in recipients. Positive cross-matches are also a contraindication to
transplantation (Esmore, 2005).

Cardiac allograft vasculopathy
Cardiac allograft vasculopathy (CAV) is the most important chronic
comorbidity in heart transplant patients. CAV is the leading single cause of retransplantation in the US, accounting for 59% of total cases (Lund et al., 2014), and
is associated with higher mortality rate at one year or five years after transplantation
(Taylor et al., 2009). The mechanism of CAV is multifactorial, with the involvement
of immune and non-immune factors (Griffin et al., 2012). These mechanisms
include conventional risk factors for atherosclerosis, pre- and perioperative injury
6

to the graft vessels, innate immunity, cell-mediated rejection and antibodymediated rejection (Pober, Jane-wit, Qin, & Tellides, 2014).
Table 3: ISHLT nomenclature for cardiac allograft vasculopathy
(Mehra et al., 2010)
ISHLT CAV0
• Not significant No detectable angiographic lesion
ISHLT CAV1 (Mild)
• Angiographic left main (LM) < 50%, or primary vessel† with maximum lesion
of <70%, or any branch‡ stenosis <70% (include diffuse narrowing) without
allograft dysfunction§
ISHLT CAV2 (Moderate)
• Angiographic LM <50%; a single primary vessel ≥70% or isolated branch
stenosis ≥70% in branches of 2 systems, without allograft dysfunction
ISHLT CAV3 (Severe)
• Angiographic LM ≥50% or two or more primary vessels ≥70% stenosis, or
isolated branch stenosis ≥70%, or ISHLT CAV1 or CAV2 with allograft
dysfunction or evidence of significant restrictive physiology$
†A “primary vessel” denotes the proximal and middle 33% of the left anterior
descending artery, left circumflex, the ramus and the dominant or co-dominant
right coronary artery with the posterior descending and posterolateral branches.
‡A “secondary branch vessel” includes the distal 33% of primary vessels or any
segment within a large septal perforator, diagonals or obtuse marginal branches
or any portion of a non-dominant right coronary artery.
§Allograft dysfunction is defined as left ventricular ejection fraction ≤45% usually
in the present of regional wall motion abnormalities.
$Restrictive cardiac allograft physiology is defined as symptomatic heart failure
with echocardiographic E to A velocity ratio >2 (>1.5 in children), shortened
isovolumetric relaxation time (<60 msec), shortened deceleration time (<150
msec), or restrictive hemodynamic value (right atrial pressure > 12 mmHg,
pulmonary capillary wedge pressure >25 mmHg, cardiac index < 2l/min/m2)
The underlying pathology of CAV is a progressive, proliferative, diffuse,
chronic inflammatory condition of allograft coronary arteries. The morphology of
CAV is concentric intimal thickening with outward remodeling, which makes it
difficult to diagnose by conventional angiography. Current antilymphocyte and
immunosuppressant have not yet yielded promising results to prevent or treat CAV.
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Therefore, identifying patients at risk and applying rigorous prevention is the
current strategy to deal with CAV.
The risk of developing CAV is higher in patients of female gender, or with
elevated pre-transplant panel-reactive antibodies (PRAs), de novo donor-specific
antibodies (DSA) after transplantation, positive donor-specific crossmatch, prior
sensitization to OKT3, cytomegalovirus (CMV) seropositivity, prior implantation of
a ventricular assist device, and re-transplantation (J. Kobashigawa et al., 2011).
Immunosuppressive agents such as cyclosporine or corticosteroid are also thought
to contribute to endothelial cell injury, and ultimately to hyperplastic characteristic
of CAV.

Mortality
The median survival time of heart transplant is 10 years. The mortality rate
is highest in the first year, primarily due to graft failure and infection. For patients
who survive the first year, the median survival time is 13 years. The improvement of
survival in the first year after transplantation contributes greatly to the general
improvement of survival of heart transplantation in the past decades, while long
term survival has not changed much.
Factors associated with mortality post-transplantation vary by time. For the
first year, mechanical circulatory bridging support, ischemic heart disease, renal
failure and mechanical ventilation are among the most significant attributors to
mortality. From one to ten years after transplantation, in addition to prior factors,
history of previous stroke, female donor or recipient are also associated with higher
mortality (David D. Yuh, Luca A. Vricella, Stephen C. Yang, John R. Doty, 2014).
8

Antibodies in heart transplantation
Human leukocyte antigen (HLA) antibodies are an important predictive
factor for allograft failure (J. A. Kobashigawa, 2007; Nikaein, Alivizatos, Monahan,
& Stone, 1995). The association between anti-HLA antibodies and cardiac allograft
rejection was first described in the 1970s (Vasilescu et al., 2004). Since then,
numerous studies have shown that the development of DSA to the HLA increased
the risk of developing CAV in heart transplant patients (Raess et al., 2013; Reed et
al., 1996; Suciu-Foca et al., 1991). The mechanism by which preexisting anti-HLA
adversely affect transplant outcome has not been understood clearly. The presence
of anti-HLA, although not directly specific against donor graft, is still associated
with rejection post-transplant. Loupy et al. reported C1q-bound anti-HLA positivity
associated with 11 times higher risk of graft lost in kidney transplantation compare
to non C1q-bound anti-HLA (Loupy et al., 2013). Loupy also suggested that
preformed C1q-bound anti-HLA had better predictive value for graft rejection than
complement dependent cytotoxicity. However, these results were still controversial
because half of patients who had been positive for C1q-bound antibodies became
negative post-transplant, and posed a smaller risk of rejection post-transplantation
(Baid-Agrawal, Lachmann, & Budde, 2014).
Recently, the role of non-donor specific antigen antibodies in graft rejection
has been the subject of interest. These non-donor-specific antibodies include, but
not limited to, antibodies against angiotensin II type 1 receptor, vimentin,
endothelial cell antigens, cardiolipin, and cardiac myosin (Barz & Rummler, 2013;
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Forman, Lin, Pascual, Denton, & Tolkoff‐Rubin, 2004; Jurcevic et al., 2001; Kalache
et al., 2011; Warraich et al., 2000).
Angiotensin II type 1 receptor (AT1R) is a transmembranous G-couple
protein receptor, that mediates the majority of the physiologic effects of Angiotensin
II, especially on blood pressure (Dzau, 2001). There are several pathways through
which a human develops antibodies against AT1R. AT1RAb can develop similarly to
HLA antibodies through blood transfusion, pregnancy, or prior transplant
(Reinsmoen, 2013). AT1RAb activate AT1R and promote remodeling of allograft
vasculature. AT1RAb was found to be associated with adverse outcomes in both
heart and kidney transplantation (Reinsmoen, 2013). In heart transplantation,
AT1RAb are linked to cell-mediated rejection (CMR), antibody-mediated rejection
(AMR), and an early CAV onset at one year after transplant (Yamani et al., 2006).
In kidney transplantation, AT1RAb are associated with AMR independently or
synergistically with HLA class II DSA in pediatric patients (Kelsch et al., 2011;
Reinsmoen, 2013). Reinsmoen et al. found an impact of AT1RAb and DSA positivity
on the development of AMR and CMR at two years after transplant. However, the
authors did not find a significant impact of AT1RAb and DSA positivity on the
incidence of mortality or CAV (Reinsmoen et al., 2014). To our knowledge, the
association between preexisting AT1RAb or anti-HLA antibodies with clinical
outcomes, such as mortality or CAV has not been well studied in heart transplant
patients.
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Study specific aim
Investigate whether the presence of antibodies against HLA or AT1R
increases the risk for cardiac allograft vasculopathy or mortality in heart transplant
patients.

Study hypothesis
We hypothesized the presences of at least one type of anti-HLA antibodies or
Angiotensin II type 1 receptor antibodies increase the risk for the development of
cardiac allograft vasculopathy or death in heart transplant patients. We also
hypothesized that AT1RAb, when being considered alone, is associated with a higher
risk of mortality or CAV.

METHODS
Study Design and participants
This was a retrospective cohort study to investigate the association between
antibody positivity and time to death or time to development of CAV. Eligible
participants included patients aged 18 or above, who had heart transplantation from
January 1st, 2007 to December 31, 2014 and received post-transplantation care at
Nebraska Medicine. A total sample of 114 participants with at least one pretransplantation antibody test record was used for analysis. The study protocol was
approved by University of Nebraska Medical Center Institutional Review Board.
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Outcomes
Our primary outcome was time to all-cause mortality and the secondary
outcome was time to the first CAV diagnosis since transplantation. Time to death
censored status calculated by time from transplantation to either the last visit or the
last day of study (31st December 2014), whichever came first. Two researchers with
formal cardiology training independently reviewed all available participants’
coronary angiographs. In case there were discrepancies of diagnoses between two
researchers, the coronary angiography results from medical record were used as a
third judgment. CAV was identified by coronary angiograph and allograft function
and physiology following the International Society for Heart and Lung Transplant
(ISHLT) 2010 guidelines. In our study, patients were considered to have CAV if they
felt into one of the categories from ISHLT CAV1 to ISHLT CAV3 and not to have CAV
if they were ISHLT CAV0. Time to CAV censored status was calculated by time from
transplantation to either the last normal angiography or the last day of study (31 st
December 2014), whichever came earlier.

Exposures
The primary exposure was pre-transplant composite antibodies to donor,
including preexisting anti-HLA antibodies class I and class II, and anti-AT1R
antibodies (AT1RAb). Participants were considered positive for composite
antibodies if they had antibodies against at least one type of HLA or AT1R. We also
conducted exploratory analyses for AT1RAb alone as the secondary exposure. We
detected anti-HLA antibodies using flow cytometric technology with LABScreen™
products. We incubated 48h-pretransplant sera with purified antigens-coated
12

microbeads and pre-optimized reagents. Any antibodies present in the patients’ sera
bound to the antigens on the beads and then were bound by anti-human IgG labeled
with R-Phycoerythrin (PE). We detected AT1RAb using ELISA assay. AT1RAb in
patient’s serum was bounded by anti-human IgG labeled with peroxidase enzyme.
Based on our laboratory protocol, AT1RAb was considered to be positive when
plasma concentration greater than 10 U/ml. Mean fluorescence intensity >3,000
and >2,500 were used as a cut off for HLA class I positive and HLA class II positive,
respectively.

Other measurements
Sociodemographic information was obtained through electronic medical
records. We categorized age as younger than 55, or 55 and above following the
median age of 55 in our sample. We classified race as two groups: white and other
races. Smoking status was divided into have ever been a smoker or have never been
a smoker. In our sample, only 3 patients were smoking at the time of transplant.
Heart disease diagnosis was either coded to ischemic or non-ischemic heart disease.

Statistical analyses
Participants’ baseline characteristics were described by univariate analyses.
We used Chi-square test or Fisher’s exact test where appropriate to compare
baseline categorical variables. We used two independent samples T-test and
Wilcoxon-signed rank test to compare continuous variables. We conducted KaplanMeier plot and a log-rank test to compare the time to event (death, CAV) by antibody
strata. In addition to the analyses for primary exposure, exploratory analyses on a
13

sample of 67 patients who were tested for AT1RAb were also conducted. We used a
2-sided alpha of 0.05 as the cut-off value for statistical significance. All the analyses
were performed in SAS 9.3 statistical software.

RESULTS
In our sample of 114 patients, 25 patients were positive for anti HLA (22%)
and 89 were negative (78%). A subsample of 67 were tested for AT1RAb, among
them 57 were positive (85%) and 10 were negative (15%).

Baseline characteristics
The median age at transplantation was 55 years, ranging from 20 to 69 years.
The distribution of age at transplantation was not different by antibody status (Table
5). Males and whites were predominant, accounting for 80-90% of the sample.
Current or past smoker tended to be more common among participants who were
negative for all antibodies compared to the positive counterparts (68% vs. 54%,
p=0.14). Similarly, hypertension tended to be more common among patients who
were negative for all antibodies compared to those who were positive (86% vs. 73%,
p=0.09). These results were also observed similarly for AT1RAb alone. The
percentage of ischemic heart disease was seen equally (40%) between the positive
and negative AT1R antibody group. However, when DSA and anti HLA were taken
into consideration, ischemic heart disease was more commonly seen in the
negativity group (62%) compared to the positive group (40%; p=0.03). Diabetes
tended to be more common in the AT1RAb positive group than in the negative group
(51% vs. 20%, p=0.09), whereas its distribution was not different (50%) between the

14

composite antibody positive and negative groups. More than 40% of participants
who were positive for at least one type of antibodies had utilized LVAD before
transplantation compared to just about 25% among participants who were negative
for these antibodies (p=0.05).

Survival analyses
Time to death
The overall mean follow up time was 69 months, ranging from 1 to 94 months
post-transplantation. Survival probability tended to be higher in antibody positive
group around the first 3 years. The probability of survival at 36 months posttransplantation was 89% in the composite antibody negative group and 95% in the
positive group (Figure 1-A). However, at the end of the study, survival probability of
antibodies positive and negative groups were not different (p=0.29). Among
participants with a valid AT1RAb test, the mean follow up time was 54 months,
ranging from 1 to 57 months post-transplantation. Three years post-transplantation,
100% of participants who were negative for AT1RAb survived and compared with
94% of participants who were positive for AT1RAb (Figure 1-B). The difference was
more prominent at the end of follow up. However, it did not reach the level of
significant.
Time to cardiac allograft vasculopathy
The overall mean follow up time for CAV was 64 months, ranging from 3 to
84 months post-transplantation. The probability of CAV-free at 36 months posttransplantation was 88% in the composite antibody negative group, while 77% of
positive group stayed free of CAV. The trend of developing CAV was not different in
15

the first 24 months after transplantation between the negative (22%) and positive
(23%) groups (Figure 1-C). However, after 35 months, CAV-free time declined more
rapidly in patients who had positive antibodies compared to those who were
negative (p=0.05). History of ischemic heart disease showed a trend of increase CAV
hazard, while hypertension associated with lower hazard. Both these trends did not
meet significant level. History of LVAD use did not affect the risk of having CAV
between composite antibody positive and negative groups. At 36 months posttransplantation, 100% of AT1RAb negative patients stayed CAV-free, compared to
only 74% in the AT1RAb positive group were free of that condition (Figure 1-D). The
decline trend was more obvious later in the follow up time in AT1RAb positive group,
although this comparison did not reach the level of significant (p=0.23).

DISCUSSION
With the improvement of survival in the first year after transplantation,
identifying risk factors that are associated with longer term complication such as
CAV and long-term mortality is the new focus to further improve prognosis of heart
transplantation. In the present study, we found an increased risk for developing CAV
among participants who had pre-formed antibodies to at least HLA or AT1R.
Preexisting anti AT1R antibodies were commonly present among heart
transplant patients in our study. The prevalence of preexisting AT1RAb was reported
from 17% to 47% among kidney transplant patients (Giral et al., 2013; Taniguchi et
al., 2013). Urban et al. reported a lower prevalence of AT1RAb (38%) among heart
transplant patients, however, the authors used higher cutoff (17U/ml) compared to
our study (10U/ml) (Urban, Gazdic, Slavcev, & Netuka, 2015). Among baseline
16

characteristics, history of LVAD use and ischemic heart disease were significantly
associated with positivity of composite antibodies. Similar association was also
noted between AT1RAb and history of LVAD use in our study and in another study
in Germen with similar percentage of AT1RAb positive in LVAD group (Sandy von
Salisch et al., 2013). The association between history of LVAD use and anti-HLA
antibodies was reported before (Kaczorowski, Datta, Kamoun, Dries, & Woo, 2013).
The mechanism by which LVAD patients became sensitized to alloantigen was not
clear. It is proposed that the exposure of blood products via transfusion in LVAD
implantation procedure could induce allosensitization (McKenna Jr., Eastlund,
Segall, Noreen, & Park, 2002). However, Drakos et al. and Itescu et al. in
independent studies found avoiding blood transfusion or applying leukocytefiltered cellular blood product did not reduce the risk of allosensitization (Drakos et
al., 2007; Itescu, Ankersmit, Kocher, & Schuster, 2000). In our study, when
considering the hazard of developing CAV, patients with history of LVAD use did
not have higher hazard than patients without LVAD use. This finding was consistent
with previous studies which found no risk of LVAD use on clinical outcome such as
mortality or CAV post-transplantation (Baran et al., 2005), even though it was
associated with positive HLA antibodies and allograft rejection (John et al., 2003).
Our study’s results suggested that positive preexisting composite antibody
participants had higher hazard of developing CAV compared to negative
counterparts. Pre-transplant anti-HLA antibodies was not associated with CAV in a
study by Gandhi (Gandhi et al., 2010). However, the sample size in that stud was
relatively small (19 patients). Eschborn in a study with 92 patients found a higher
prevalence of CAV among preexisting HLA antibody patients compared to negative
17

counterparts, but the authors failed to establish a statistical difference (Eschborn et
al., 2013). The mechanism by which HLA antibodies acquire their effect on
vasculopathy is mainly via transplant rejection. Circulating antibodies attack donor
antigen on the graft, activate complement system, cause C4d deposition on
endothelial cells and start inflammation processes. In our study, the difference of
CAV risk was not evident in the first 24 months after transplantation between then
composite antibody positive and negative groups. This finding was consistent with
the knowledge that CAV usually develops later in the course of transplantation, in
the relation with both cell mediated and antibody mediated chronic rejection.
The increase risk of developing CAV also noted when only AT1RAb positivity
was taken into account in our study. AT1RAb was found to be associated with early
onset of microvasculopathy in heart transplant before (Hiemann et al., 2012). The
transplant procedure itself or the ischemic condition post-transplant promotes the
expression of AT1R on endothelial cells and the development of AT1RAb
(Reinsmoen, 2013). Since Angiotensin II also functions as moderator for cell
growth, apoptosis, fibrosis and inflammation (Ruiz-Ortega et al., 2001),
upregulating AT1RAb is thought to be associated with endothelial activation,
leading to smooth muscular cell proliferation and microvascular disease
(Reinsmoen, 2013). In our study, all patients without antibody against AT1R were
free of CAV in the follow up time while the patients with AT1RAb accumulated CAV
along with time. Although the follow up time and the number of participants in the
AT1RAb negative group were relatively shorter and smaller than those in the
positive group (Figure 1-D), we expect to see the trend to continue when more
patients are enrolled and followed for a longer time in the future.
18

In our study, participants who were positive for either donor specific antigen
or AT1R did not showed higher mortality hazard compared to negative counterparts.
Although post-transplant anti HLA antibodies were found to increase the risk of
mortality in heart transplant, preexisting antibodies against HLA were not clearly
associated with mortality in these patients (Ho et al., 2011). Tambur et al. found that
majority of pre-existing anti HLA antibodies do not act directly against donor
antigen found by lymphocyte cross match (Tambur et al., 2000). Thus, these
antibodies would not trigger vigorous immune activity against the allograft,
especially under the immunosuppressive therapy post-transplantation. When
AT1RAb was considered alone, there was a minor trend of worse survival outcome
in positive participants after 24 months. Due to no event in the AT1RAb negative
group and short follow up period, mortality hazard ratio was not calculated for
AT1RAb status. This finding calls for further investigation on the role of preexisting
AT1RAb on mortality in heart transplant patients.
Our study has some limitations. First, our sample was relatively small, which
reduced our ability to detect small differences or conduct subgroup analyses. The
selection of participants based on availability of test results could have introduced
selection bias. On the other hand, our study was among the first study to look at the
predictive value of AT1RAb on CAV and survival in heart transplantation. The
assessment of CAV was done by two independent researchers, which would reduce
observer bias. Future studies would assess the relationship between antibodies and
CAV or mortality over a longer period of time, or evaluate the potential interaction
between AT1RAb and donor specific antibodies on clinical outcomes in heart
transplant patients.
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Importance of the Capstone project
This study allowed us to better understand the involvement of donor specific
antibodies and non-donor specific antibodies, more specifically, anti-HLA
antibodies and AT1RAb in the development of cardiac allograft vasculopathy as well
as survival. This knowledge can help cardiologists identify the best donor-receiver
match for transplant as well as transplanted patients who are at higher risk for these
conditions. Further, these knowledge can be translated into a more appropriate
prevention or treatment strategy for high risk heart transplant recipients.
For the public health, the study’s finding can contribute to better outcomes
of heart transplantation, including lower re-transplant rates, mortality and
dysfunction in heart transplantation. Further, these better outcomes will result in
more patients receiving heart transplant, less medical cost and more effective and
efficient heart transplantation programs.
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Table 5: Pre-transplantation characteristics of participants by
positivity to pre-transplant antibodies (n=114)
Characteristics
Age
<55
≥55
Gender
Male
Females
Race
White
Others
Smoking status†
Never smoker
Ever smoker
Heart disease
Ischemic
Non-ischemic
Diabetes
Yes
No
Hypertension
Yes
No
Hyperlipidemia
Yes
No
LVAD
Yes
No

Composite antibodies‡
Positive
Negative p-value
(n=70)
(n=44)
n (%)
n (%)
0.95
33 (47)
21 (48)
37 (53)
13 (52)
0.67
55 (79)
36 (82)
15 (21)
8 (18)
0.99*
64 (91)
40 (91)
6 (9)
4 (9)
0.14
31 (46)
36 (54)

13 (32)
28 (68)

Anti AT1R antibodies
Not tested Positive Negative p-value
(n=47)
(n=57)
(n=10)
n (%)
n (%)
n (%)
0.99*
20 (43)
29 (51)
5 (50)
27 (57)
28 (49)
5 (50)
0.99*
37 (79)
46 (81)
8 (80)
10 (21)
11 (19)
2 (20)
0.99*
44 (94)
51 (89)
9 (90)
3 (6)
6 (11)
1 (10)
0.49*
15 (36)
37 (64)

26 (46)
30 (54)

3 (30)
7 (70)

0.05
18 (40)
42 (60)

26 (59)
18 (41)

0.99*
27 (57)
20 (43)

23 (40)
34 (60)

4 (40)
6 (60)

0.99
35 (50)
35 (50)

22 (50)
22 (50)

0.09*
26 (55)
21 (45)

29 (51)
28 (49)

2 (20)
8 (80)

0.09
51 (73)
19 (27)

38 (86)
6 (14)

0.43*
39 (83)
8 (17)

41 (72)
16 (28)

9 (90)
1 (10)

0.43
46 (66)
24 (34)

32 (73)
12 (27)

0.73*
35 (74)
12 (26)

37 (65)
20 (35)

6 (60)
4 (40)

0.05
30 (43)
40 (57)

11 (25)
33 (75)

0.17*
11 (23)
36 (77)

28 (49)
29 (51)

2 (20)
8 (80)

AT1R: Angiotensin II type 1 receptor, LVAD: Left ventricular assist device.
All the p-values are from Chi-Square test comparing the positive to the negative groups, otherwise
stated.
*p-values from Fisher’s exact test comparing the positive to negative group.
†Sum less than total due to missing values.
‡Composite antibodies positive if positive for at least one of anti-HLA class I and II or AT1R
antibodies.
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Log-Rank p=0.29

A

Log-Rank p=0.46

B

Composite antibody positive (n=70)
Composite antibody negative (n=44)

AT1RAb positive (n=57)
AT1RAb negative (n=10)

Log-Rank p=0.05

C

Composite antibody positive (n=66)
Composite antibody negative (n=37)

Log-Rank p=0.23

D

AT1RAb positive (n=56)
AT1RAb negative (n=10)

Figure 1: Post-transplantation survival time by composite antibody status (DSA class I, II, anti HLA class
I, II and AT1RAB) in (A) or by AT1RAb in (B) and cardiac allograft vasculopathy (CAV) free time by
composite antibody status in (C) or by AT1RAb in (D).
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SERVICE LEARNING REFLECTION
Organization
DIVISION OF CARDIOLOGY, DEPARTMENT OF INTERNAL MEDICINE, UNMC

The Division of Cardiology has 23 physicians. Its physicians are subspecialized in
cardiac electrophysiology, interventional cardiology, diagnostic cardiovascular
imaging, heart failure and heart transplantation (University of Nebraska Medical
Center, 2014).
ORGANIZATION FUNCTION

The division of Cardiology functions as both a treatment center and an
academic center. The Division provides patient care services to all adults with
various type of cardiovascular disease, ranging from ischemic heart disease, valvular
heart disease, arrhythmia, heart failure, and heart transplantation care. The
cardiologists work closely with thoracic surgeons to provide the exceptional,
comprehensive medical and surgical cardiovascular care.
In addition to patient care services, the Division of Cardiology providing
support for medical student, resident, and cardiology fellow training. The Division
also offers clinical and research oriented conferences. The Division is also actively
involved in research, ranging from bench research to clinical and community based
research (University of Nebraska Medical Center, 2014).
ORGANIZATION AIMS

•

Working with surgical partners to become a destination for patients to
receive exceptional, comprehensive medical and surgical cardiovascular care.
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•

Be nationally recognized for our research programs.

•

Be a leader in innovative educational programs for students, house officers
and clinicians across the region and provide

•

Attract and retain top clinicians, educators and scientists.

Service performed
The Service learning activities was conducted in the 2015 spring semester,
from January 2015 to May 2015. The goal of the service that student provides to the
site was to create a dataset that contains heart transplant patients which would be
used for future research activities.
A part of the Service Learning activities, the student reviewed coronary
angiographs of heart transplant patients. The results then transferred into electronic
records with corresponding anatomical lesions. For each patient, the coronary
angiograph results included the latest test, if those patients did not have any
coronary artery lesion on the film, or the earliest angiograph that showed abnormal
anatomy if they had coronary artery lesions.
Student also reviewed echocardiograph and cardiac catheterization results
from the medical record system (EPIC) for patients who have lesions on coronary
angiography. The results were recoded into electronic form which contains left
ventricular ejection fraction, right atrial pressure, pulmonary arterial pressure,
diastolic function, and cardiac index. The results of coronary angiography,
echocardiography and cardiac catheterization then graded for diagnosing of cardiac
allograft vasculopathy following the International Society of Heart and Lung
Transplantation guidelines.
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In the second part of the Service learning, the student created an online
database using REDCap web application. The REDCap database contained heart
transplant patients currently in the research projects of the Cardiology Division. The
variables were organized by variable domains, which included pre-transplantation
variables, post-transplantation variables and donor-related variables. The database
is able to be added more records in the future when the projects go on. Access and
right of modification to the database can be granted by Dr. Brian Lowes. The
REDCap database will be maintained and used for research activities of the Division
in the future.

Learning experience
When I came to UNMC, Vietnam started heart transplant program with the
first four patients. Sadly, after 6 months, all patients died because of acute rejection,
a catastrophic complication that has been well prevented and treated in the US for
the last ten years. The service learning and capstone project provides me a
wonderful opportunity to pursuit my interest and apply my knowledge and skills.
The first thing I learned from this project was current literature on heart
transplantation, which provided me a more comprehensive view of transplantation
process, from selecting the patients, selecting donor, screening and matching donorrecipient, post-transplant care and especially the role of antibodies in heart
transplantation. From literature review, I also identified potential risk factors for
mortality or CAV in heart transplant recipients. This knowledge was applied to
identify potential confounders or interactions in our analysis plan. Secondly, this
was my first time to conduct a longitudinal study. I have learned the vital role of
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time measurement for both exposures and outcomes, and how an obscure
measurement could largely distort the relationship. More important, I learn how to
apply epidemiology to test a scientific hypothesis, and ultimately to improve quality
of patient care and common health at large.
The second big gain was my experience of using REDCap. REDCap is a secure
web application, developed by Vanderbilt University, for building and managing
online surveys and databases. The application offers many options for designing
questionnaire, checking data quality, export data dictionary or copy the format and
structure of the project to use in a similar study. There is also a REDCap shared
library of validated instruments and forms that can be easily downloaded and used
by researchers partnered with REDCap. While working on service learning, I had an
opportunity to explore and use most of the relevant options in REDCap.
The biggest challenge to me was how to coordinate and collaborate between
a busy research team. The challenge can be as simple as how to set up a meeting
with the committee members or with members in the team to more complicated as
how to exploit the expertise of each member of the project in the most valuable way.
For these challenge the best way for me was to discuss with my advisor and other
students to collect their experience, and plan everything in advance.

Administrative Resources
Offices supplies such as paper, pen, copying and printing are self-supported
by students and committee members. Student used SAS 9.3 statistical software for
all the analysis. SAS 9.3 is provided free of charge to all College of Public Health
students through secure clustered computers in the computer lab. Rooms for
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committee meetings are located in College of Public Health, which is provided by
the college for Service Learning and Capstone Projects. No travel will be needed to
accomplish the course. Other costs will be covered by the student.

Service Learning/ Capstone Experience Goals and Objectives
Goal 1: Completing service learning in spring semester
Objective 1: Creating a REDCap database for data entry.
Objective 2: Read coronary angiographs of heart transplant patients
Objective 3: Enter data into the REDCap project
Goal 2: Completing capstone experience in summer semester
Objective 1: Analyze data for study questions
Objective 2: Write and review the Capstone Experience report and
manuscript
Objective 3: Prepare and defend the capstone experience and submit paper
TIMELINE FOR SERVICE LEARNING AND CAPSTONE EXPERIENCE

The timeline for Service Learning and Capstone Experience is depicted
bellow:
Table 4: Timeline for Service Learning and Capstone Project
Spring Semester
Summer Semester
Service Learning
Objective 1
X
Objective 2
X
Objective 3
X
Capstone Experience
Objective 1
X
Objective 2
X
Objective 3
X
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ETHICS ISSUES REGARDING RESEARCH
PROTECTION OF PERSONAL IDENTIFICATION

Since the data that we used include critical personal identification of the
patients, there was a chance that such information might accidently be disclosed
and/or obtained by a third party without the authorization of participants. To avoid
any unauthorized access, all the data were stored in encrypted computer inside
locked cabins or rooms. All personal identification was available only to the
investigators. The access of personal identification to collaborators in the future can
be safely granted by Dr. Lowes via REDCap project. All the statistics analysis was
processed at secure computer lab at College of Public Health, UNMC.
SAFETY OF SUBJECTS

This was a retrospective study. All the information was available from the
electronic health record system or in other hard copy forms. No procedure or
medication was applied to patients for purpose of this study. Post-transplantation
care was given to patients regardless of participation status. Other safety procedures
were followed at the primary clinical trial and were approved by the UNMC IRB.
Therefore, this study is considered to be minimal risk.
CONFLICTS OF INTEREST

The student and other researchers declare that they have no conflict of
interest. The student, Hoang Tran, received a fellowship from the Vietnam
Education Foundation to support his study at UNMC. The fellowship has no known
benefits from this study.
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APPLICATION OF PUBLIC HEALTH COMPETENCIES
Competency
Activity/Application

Reflection of Competency Strength/
Professional Growth

Committee
Assessment

CORE COMPETENCIES
Competency 1B: Applied
descriptive and inferential
methodologies according to the
type of study design
Activity/Application:
Applied univariate analysis with
Chi-Square and Fisher’s Exact
tests to describe the baseline
characteristics. Applied Kaplan
Meier curve and Log-Rank test
to compare time to events.
Applied Cox proportional
regression to estimate hazard
ratios for interest predictors
Competency 1C: Interpret
results of statistical analyses in
public health studies.
Activity/Application:
Interpreted results from
analysis, presented data in a
variety of formats: table, plots,
narrative.

Competency 3B: Identify key
sources of data for
epidemiological purposes.
Activity/Application:
Identified potential source
epidemiological data for
Capstone Experience.

Competency 7A: Identify and
apply fundamental research skills
in public health.

This was my first time to apply survival
analysis outside class. There were several
factors that need to be considered when I
conducted survival analyses which were not
relevant to logistic regression analyses that I
have done before. These factors such as time
of exposure, or variability of exposures (DSA,
AT1RAb) along the follow up time could
affect the accuracy of the measurement and
there for bias the results. These factors
should always be taken account in the plan of
data collection and efforts to identify these
potential bias should be made in order to
have accurate results.
Interpreting the results in my project was
challenging. Because of the unexpected
missing data on CAV outcome, I have less
power to detect small differences. For
example, although the Kaplan Meier curves
showed different patterns between the
negative and positive exposure groups, the pvalue was still non-significant. Therefore,
recognizing the trends or evaluating the
absolute estimates, and confident intervals
was important in interpreting the results
rather than just focusing on p-value.
I was able to identify several sources of
epidemiological data such as Maine’s
Behavior Risk Factor Survey (BRFSS),
Veteran Affair Hospital Rheumatoid Arthritis
Registry (VARA), and California Health
Interview Survey. In my project, the data
mainly came from NMC electronic medical
records (EPIC). EPIC can be a very good
source of research data with lots of
information such as history, laboratory tests,
comorbidities, procedures and treatments.
However, some of the information was
stored in an unextractable forms such as pdf
or scanned pictures, which requires
researchers to manually mine the data.
From the Capstone experience paper, I was
able to write a scientific manuscript which
could be submitted for publication in a peerreview journal. The challenge that I faced to
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Activity/Application: Applied
research skill to write a scientific
manuscript.

Competency 10A: Applied
ethical principles to the collection,
maintenance, use, and
dissemination of public health
information.
Activity/Application: Secured
patients’ confidentiality and safety
throughout the study

when I transformed the paper into the
manuscript was the succinct format of the
manuscript. Unlike the paper which was
relatively flexible in format, the manuscript
needed to be very concise, with around 3,000
words to covey the study findings and
discussion, in addition to a throughout and
detailed method description.
Although my study was a retrospective
cohort study and no procedures, drugs or
experiments were given to the patients, we
dealt with lots of personal information which
also need to be secured. I always adhered to
patients’ information protection rule in my
study. All the data were stored or transferred
via HIPPA-compliant, secured server
provided by UNMC information services.
Data were not exposed to anyone who did
not have the right to access determined by
UNMC IRB.
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CONCENTRATION COMPETENCIES
Competency 1A:
Conceptualize epidemiologic
research questions and
hypotheses.
Activity/Application:
Created study objectives and
hypotheses
Competency 1C: Review and
critique published
epidemiologic studies.
Activity/Application:
Reviewed and critiqued
published epidemiologic
studies. Compared previous
studies’ findings with the
present study’s findings.
Competency 3A: Choose a
study design appropriate for a
particular epidemiologic
question
Activity/Application: Chose
retrospective cohort study as
the design for my Capstone
project.

From literature review, I was able to identify
the potential association between AT1RAb
and CAV or mortality following heart
transplant and propose the testable
hypotheses through which AT1RAb affect
heart transplant patients. I also identify the
knowledge gap and proposed the study
objective to fill in the gap.
There were a bundle of literature related to
heart transplant and post-transplant
complications or mortality. I was able to
review the current literature to describe the
donor-recipient selection process, which
essential to understand the role of antibodies
in rejection post-transplant. I also compared
the findings in my study with previous
studies, and discussed potential explanation
for any differences among the findings.
Choosing the proper study design to test the
study hypotheses is crucial. With the current
data, I was be able to conduct a case-control
study or a retrospective cohort study. The
case-control study would be easier for me to
conduct since I was familial with logistic
regression. Since the study outcomes (CAV,
death) would not occur at once, the casecontrol study would not be able to reflect
time to event and therefore would fail to test
the hypotheses. On the other hand, a
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Competency 4c: Identify
potential sources and effects of
bias in epidemiologic studies.
Activity/Application:
Identified potential bias in the
present study and minimized
the bias by analytical method.

retrospective cohort study would enable to
measure time from transplant until the
occurrence of outcomes, which will provide
more information in the results, even with
potential explanation of the underlying
mechanism.
The present study employed time to event
analyses. Besides the potential confounders
that can affect the association (which
partially adjust in multivariate analyses),
time measurement of exposures or outcomes
can also bias the results. For example, if the
preexisting antibody status change, measure
it at one point in time would potentially
resulted in different result if it was measured
in another time point. Therefore, the
classification of patients to either exposed or
non-exposed group could be changed.
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